Looking to relocate, expand, or start a bioscience enterprise?
Then it's time to take a look at Maryland. We're confident
that the closer you look, the more you'll like what Maryland
has to offer.
. More than 380 bioscience companies-one of the fastest
growing clusters in the U.S.
. Ranks second per capita in federal R&D obligations-$12.2
billion
. State investment of over $450 million in bioscience
infrastructure
. Access to partners, major research universities,
and federal institutions, most within an hour of each other
. Second ranked among U.S. states in the percentage
of professional and technical workers (25.7%) in the workforce
. First among the states in per capita number of doctoral
scientists in health and biological sciences.
Global Reach, Local Access
What's the strategic advantage of a Maryland
location In a word, ACCESS . To your customers. To competitors.
To potential partners. And to the rest of the world.
Located halfway between Boston and Atlanta, London and Los
Angeles-and with 90 percent of the state's bioscience assets
less than an hour away from each other-Maryland is where
the bioscience industry comes together to develop and market
new products and technologies.
What better way to ensure access to every corner of the
U.S. and world markets than to situate your new or expanding
business at the epicenter of the global bioscience community?
Strength and Numbers
Maryland boasts one of the fastest growing bioscience
clusters in the United States, and the state continues to
attract established industry leaders and entrepreneurs to
the area. With all the significant regulatory agencies like
the Food and Drug Administration (FDA) just a short drive
away, Maryland businesses can save both time and money-especially
in the areas of new drug and device applications and clinical
trial reviews.
. Home to eight percent of the U.S.
bioscience market
. More than 380 bioscience companies conducting biopharmaceutical
discovery, developing new devices, diagnostics and research
tools, and breaking new ground in bioinformatics
. Home to 17 publicly traded companies, along with
more than 20 companies conducting clinical trials for new
biotherapeutics
Some of Maryland's leaders and innovators in bioscience
include:
. Biotherapeutics and Diagnostics - MedImmune,
Human
Genome Sciences, Celera,
GenVec,
Martek,
Otsuka,
BD
Diagnostics, Life
Technologies and Qiagen
. Agricultural Biotechnology - Beltsville
Agricultural Research Center, Center
for Biosystems Research and Center for Advanced
Research in Biotechnology II
. Pharmaceutical & Biomanufacturing/Bioprocessing
- Lonza,
Chesapeake
Biological Laboratories, Shire
Manufacturing, and Pharmaceutics
International
. Contract Research Services - Battelle,
Fischer
Bioservices, Lonza,
SAIC, SNBL,
and Westat.
An Exceptional Workforce
With greater than 34,000 private sector bioscience
employees, and a comparable number in university and federal
research institutions, Maryland's workforce quality and
availability are the direct result of two decades of funding
initiatives aimed at educating our workforce for a 21st
century high-tech economy:
.
Second ranked among U.S. states (25.7%) in percentage of
professional and technical workers in the workforce
.
Ranked second in concentration of doctoral scientists and
engineers, including first in Health Sciences and second
in Bio and Agricultural Sciences
.
Second ranked among the states in percentage of population
25 or older who hold a bachelor's degree or higher (35.1%)
An Atmosphere of Creative Innovation
Home to more than 50 life science research-intensive federal
institutions, several world-class academic institutions, an
ever-expanding number of private research facilities-and recipient
of $12.2 billion in federal R&D obligations-Maryland's
bioscience economy is driven by, and rooted in, an atmosphere
of creative innovation and entrepreneurial spirit.
Recognizing that basic research is the cornerstone of technical
innovation, Maryland has invested over $450 million in bioscience
infrastructure, including $100 million in 2004 alone. The
result is a unique atmosphere in which energy and resources
help push ideas forward, with more momentum and a higher degree
of participation across public and private sectors than is
present in other areas.
Maryland's leading R&D facilities in bioscience include
federal powerhouses such as:
. National
Institutes of Health (NIH)
.
Food
and Drug Administration (FDA)
.
Beltsville
Agricultural Research Center (USDA-BARC)
.
National
Institute of Standards and Technology (NIST)
.
J. Craig Venter
Institute (JCV)
And Maryland institutions such as:
.
The Johns
Hopkins University's Applied Physics Laboratory (APL)
.
The
Science Technology Park at Johns Hopkins
.
Center
for Environmental Energy at the University of Maryland
(CEEE)
.
University
of Maryland Biotechnology Institute (UMBI), including
its Institute
of Human Virology (IHV), Center
for Advanced Research in Biotechnology (CARB), Center
of Marine Biotechnology (COMB), Medical
Biotechnology Center (MBC), and the Center
for Biosystems Research (CBR)
.
UMB BioPark
, which includes 750 square feet o f short-term, pre-built
lab space for early-stage bioscience companies in its BioInnovation
Center
.
University
of Maryland M Squared Research Park , a dynamic location
for science and technology companies in College Park adjacent
to a top ranking U.S. public research university.
A Business-Friendly Environment
According to Entrepreneur magazine, the State of Maryland
- through the Maryland Venture Fund and the Technology Development
Corporation (TEDCO) - was the most active early-stage investor
in the U.S. in 2006. Years of close coordination between the
public and private sectors have helped Maryland formulate
and execute a strategic plan to support the formation, expansion
and growth of bioscience businesses-and to encourage entrepreneurship
and excellence across the industry.
.
Maryland's investment in bioscience has helped with projects
such as the ongoing renovation of the University of Maryland's
Bioprocessing
Scale-up Facility (BSF) and the opening of the cGMP
facility at UMBI Shady Grove.
.
Maryland
Technology Development Corporation (TEDCO) enables assistance
programs aimed and supporting the transfer and commercialization
of technology developed in university and federal labs.
.
Maryland
Venture Fund , financed and operated by DBED, makes direct
equity investments in emerging technology and life sciences
companies.
Maryland companies also benefit from the state's commitment
to incubators, partnerships and alliances aimed at helping
businesses thrive. Key bioscience partners include:
.
MdBio, Inc.
.
Maryland
Technology Development Corporation (TEDCO)
For more details or specific assistance regarding biosciences
business in Maryland, contact the specialist at 86 21 23081108
or cindycheng@mccusa.org.
|
